Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315906Botanical Extracts and Compounds from Schinus Plants and Methods of Use
US 14.10.2021
Int.Class A61K 31/569
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
569substituted in position 17 alpha, e.g. ethisterone
Appl.No 17357353 Applicant Emory University Inventor Cassandra L. Quave

This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

2.20210317207ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
US 14.10.2021
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17206550 Applicant ImmuNext, Inc. Inventor Randolph J. NOELLE

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

3.20210315872COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR
US 14.10.2021
Int.Class A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Appl.No 16843700 Applicant Plexxikon Inc. Inventor Wayne Spevak

Disclosed are compounds of Formula I:

embedded image

    • or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.

4.20210316003BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY
US 14.10.2021
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No 17206388 Applicant Thomas M. Cardillo Inventor Thomas M. Cardillo

The present invention relates to biomarkers of use for treating Trop-2 expressing cancer with an anti-Trop-2 ADC comprising an anti-Trop-2 antibody conjugated to an inhibitor of topoisomerase I, preferably SN-38 or DxD. The anti-Trop-2 ADC may be administered as a monotherapy or as a combination therapy with one or more anti-cancer agents, such as DDR inhibitors. Therapy with the ADC alone or in combination with other anti-cancer agents can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth. In specific embodiments, the biomarker may relate to a gene selected from the group consisting of BRCA1, BRCA2, CHEK2, MSH2, MSH6, TP53, CDKN1A, BAG6, BRSK2, ERN1, FHIT, HIPK2, LGALS12, ZNF622, AEN, SART1, USP28, GADD45B, TGFB1, NDRG1, WEE1, PPP1R15A, MYBBP1A, SIRT1, ABL1, HRAS, ZNF385B, POLR2K and DDB2.

5.WO/2021/203798USE OF SPLICING FACTOR PRPF31 INHIBITOR IN PREPARING DRUG
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/CN2021/073519 Applicant CHINA PHARMACEUTICAL UNIVERSITY Inventor XIA, Yuanzheng
Provided is a use of a splicing factor PRPF31 inhibitor in preparing a drug for preventing and/or treating cancer. The splicing factor PRPF31 can be used as a cancer treatment target. Knocking down PRPF31 or stably transfecting shPRPF31 significantly inhibits the growth of cancer. In addition, the expression level of PRPF31 in most cancer tissues is higher than that in corresponding normal tissues, and the high expression of PRPF31 makes the prognosis of cancer poor.
6.WO/2021/203828USE OF INHIBITOR IN PREPARATION OF DRUGS FOR TREATING SARS-COV-2 PNEUMONIA AND COMPLICATIONS THEREOF
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/CN2021/075757 Applicant ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Inventor WEI, Congwen
Provided is the use of an inhibitor in the preparation of drugs for treating SARS-CoV-2 pneumonia and complications thereof, wherein the inhibitor has one or more of the following properties: (1) reducing the binding of high-density lipoprotein to a receptor thereof; and (2) reducing the binding of the S protein of SARS-CoV-2 virus to cholesterol.
7.WO/2021/206078MEDICINE FOR KILLING TUMOR CELLS
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2021/014588 Applicant PHOTOQ3 INC. Inventor TODA Naoko
The present invention addresses the problem of providing a medicine for killing tumor cells, said medicine having few side effects. According to the present invention, provided is a medicine, said medicine comprising a conjugate of a substance capable of binding to a target substance on the surface of tumor cells and a cytotoxin, and a photosensitive dye, and being for killing tumor cells in which the target substance is expressed in a small amount.
8.WO/2021/207218TREATMENT OF NIDOVIRALES INFECTION WITH ERITORAN
WO 14.10.2021
Int.Class A61K 31/7024
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7024Esters of saccharides
Appl.No PCT/US2021/025987 Applicant EISAI R&D MANAGEMENT CO., LTD. Inventor GUSOVSKY, Fabian
Embodiments are directed to eritoran or a pharmaceutically acceptable salt thereof for use in methods for treating nidovirales infections in a subject, preferably selected from the group consisting of coronavirus, aterivirus, ronivirus, and mesonivirus.
9.20210315809ORAL CARE COMPOSITIONS AND METHODS
US 14.10.2021
Int.Class A61K 9/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
68chewing gum type
Appl.No 17227978 Applicant Per Os Biosciences, LLC Inventor Robert Estey

Oral formulations include a polysaccharide, such as, chitosan and an anthocyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.

10.20210315802FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES
US 14.10.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No 17346874 Applicant Intelgenx Corp. Inventor Rodolphe Obeid

An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.